Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

‘COMBATcancer’ (Combined Molecular Analysis of Blood and Tissue in cancer) is a programme initiated by the CRUK Oxford Centre in 2023.

COMBAT logo

We are analysing paired blood and tissue samples from patients with different cancers by multiple different techniques using a core common framework. We will probe tissue from different tumour regions to provide some spatial resolution and heterogeneity analysis. Integrating these data alongside electronic health records will allow us to identify novel disease-related features that could be harnessed for earlier diagnosis and/or new treatment options.

OMBATcancer is organised into multiple work packages which perform different analysis on samples from the same patient. These morpho-molecular data are integrated together with electronic health records with the aim of identifying novel features across cancers and related inflammatory conditions that can serve as novel biomarkers and/or therapeutic targets.

 

More specifically, we aim to:

  • Establish common laboratory and analytical frameworks;
  • Bring together researchers from different disciplines;
  • Identify novel morpho-molecular features across cancers and related inflammatory conditions;
  • Leverage resources to add value to existing data;
  • Provide a multimodal data resource for researchers.

Contact

For more details about the project, contact Beth Mann.

COMBATcancer is organised into multiple work packages which perform different analysis on samples from the same patient. These morpho-molecular data are integrated together with electronic health records with the aim of identifying novel features across cancers and related inflammatory conditions that can serve as novel biomarkers and/or therapeutic targets.